Trevi Therapeutics Inc (TRVI)

$11.01 -0.19 (-1.70%)
Market Cap 1.41B
Revenue (ttm) 0.00
Net Income (ttm) -47.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 984,100
Avg Vol 1,390,446
Day's Range N/A - N/A
Shares Out 128.23M
Stochastic %K 8%
Beta 0.94
Analysts Strong Sell
Price Target $21.50

Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough i...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 304 2499
Address:
195 Church Street, 16th Floor, New Haven, United States
jlcrane
jlcrane Mar. 12 at 2:18 PM
$TRVI Down 5% on 95k shares? What a bunch of idiots.
0 · Reply
abcdzepeda
abcdzepeda Mar. 11 at 3:29 PM
$TRVI now I know the reason for the price drop, we are 2 1/2 years away from an approval. Oh well, I guess I will just keep adding until we get approved. 
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 4:50 PM
$TRVI RSI: 63.04, MACD: 0.3482 Vol: 0.94, MA20: 11.49, MA50: 11.32 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
jlcrane
jlcrane Mar. 10 at 4:00 PM
$TRVI Fucking company. Time and again they kill the rally.
1 · Reply
thefourpercent
thefourpercent Mar. 10 at 12:18 PM
$TRVI still not concerned
0 · Reply
thefourpercent
thefourpercent Mar. 9 at 11:01 PM
$TRVI will exit tomorrow probably around 3% profit. Expect it to do better though.
0 · Reply
focafoca99
focafoca99 Mar. 9 at 9:51 PM
$TRVI Phase 1, 2, and 3 references all showed up
0 · Reply
mikesterz7
mikesterz7 Mar. 9 at 9:28 PM
$TRVI The company also said that it has secured FDA alignment on the remaining early-stage trials needed to support an application to the agency seeking approval.
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 9 at 8:54 PM
TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns $TRVI $IWM $VXF https://stocktwits.com/news/equity/markets/trvi-stock-slips-after-company-plans-parallel-trials-in-lung-disease/cZdVDFCRIeE
0 · Reply
notreload_ai
notreload_ai Mar. 9 at 7:34 PM
$TRVI shares plunged despite positive FDA alignment for Haduvio in IPF chronic cough. Plans for two Phase 3 trials (instead of one) triggered sell-off; Stifel holds Buy rating on the de-risked program. https://notreload.xyz/fda-clears-path-for-haduvio-but-trevi-safe-two-trial-plan-sends-trvi-down/
1 · Reply
Latest News on TRVI
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

Mar 10, 2026, 4:05 PM EDT - 4 days ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

Mar 9, 2026, 7:30 AM EDT - 6 days ago

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

Trevi Therapeutics to Participate in Upcoming March Conferences

Mar 2, 2026, 7:30 AM EST - 13 days ago

Trevi Therapeutics to Participate in Upcoming March Conferences

Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 7:30 AM EST - 26 days ago

Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)

Jan 22, 2026, 12:30 PM EST - 7 weeks ago

Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)

Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:30 AM EST - 2 months ago

Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

Dec 4, 2025, 7:30 AM EST - 3 months ago

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond

Dec 3, 2025, 2:16 PM EST - 3 months ago

Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond

Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 9:21 PM EST - 4 months ago

Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript

Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 13, 2025, 4:05 PM EST - 4 months ago

Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Nov 6, 2025, 4:05 PM EST - 4 months ago

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:30 AM EST - 4 months ago

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

Oct 8, 2025, 7:30 AM EDT - 5 months ago

Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

Sep 18, 2025, 7:30 AM EDT - 6 months ago

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 7:15 PM EDT - 6 months ago

Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Trevi Therapeutics to Participate in Upcoming September Conferences

Aug 28, 2025, 7:30 AM EDT - 7 months ago

Trevi Therapeutics to Participate in Upcoming September Conferences

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 1:47 PM EDT - 7 months ago

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

Jul 31, 2025, 4:05 PM EDT - 8 months ago

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

Trevi Therapeutics to Participate in Upcoming August Conferences

Jul 29, 2025, 7:30 AM EDT - 8 months ago

Trevi Therapeutics to Participate in Upcoming August Conferences

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

Jul 1, 2025, 7:30 AM EDT - 9 months ago

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jun 5, 2025, 4:30 PM EDT - 10 months ago

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Jun 3, 2025, 10:15 PM EDT - 10 months ago

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Jun 2, 2025, 4:01 PM EDT - 10 months ago

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

Jun 2, 2025, 1:42 PM EDT - 10 months ago

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Jun 2, 2025, 7:00 AM EDT - 10 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Jun 1, 2025, 4:00 PM EDT - 10 months ago

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Trevi Therapeutics to Participate in Upcoming June Conferences

May 29, 2025, 7:30 AM EDT - 10 months ago

Trevi Therapeutics to Participate in Upcoming June Conferences

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

May 20, 2025, 7:00 AM EDT - 10 months ago

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

May 11, 2025, 4:16 AM EDT - 11 months ago

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 8, 2025, 4:05 PM EDT - 11 months ago

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

May 1, 2025, 4:05 PM EDT - 11 months ago

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 6:47 PM EDT - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Mar 18, 2025, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

Mar 10, 2025, 11:30 AM EDT - 1 year ago

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Mar 10, 2025, 6:00 AM EDT - 1 year ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Mar 9, 2025, 4:00 PM EDT - 1 year ago

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Feb 27, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Feb 25, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Jan 30, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Dec 16, 2024, 7:36 AM EST - 1 year ago

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Dec 12, 2024, 9:47 AM EST - 1 year ago

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Dec 12, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Dec 3, 2024, 4:05 PM EST - 1 year ago

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:54 PM EST - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript

jlcrane
jlcrane Mar. 12 at 2:18 PM
$TRVI Down 5% on 95k shares? What a bunch of idiots.
0 · Reply
abcdzepeda
abcdzepeda Mar. 11 at 3:29 PM
$TRVI now I know the reason for the price drop, we are 2 1/2 years away from an approval. Oh well, I guess I will just keep adding until we get approved. 
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 4:50 PM
$TRVI RSI: 63.04, MACD: 0.3482 Vol: 0.94, MA20: 11.49, MA50: 11.32 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
jlcrane
jlcrane Mar. 10 at 4:00 PM
$TRVI Fucking company. Time and again they kill the rally.
1 · Reply
thefourpercent
thefourpercent Mar. 10 at 12:18 PM
$TRVI still not concerned
0 · Reply
thefourpercent
thefourpercent Mar. 9 at 11:01 PM
$TRVI will exit tomorrow probably around 3% profit. Expect it to do better though.
0 · Reply
focafoca99
focafoca99 Mar. 9 at 9:51 PM
$TRVI Phase 1, 2, and 3 references all showed up
0 · Reply
mikesterz7
mikesterz7 Mar. 9 at 9:28 PM
$TRVI The company also said that it has secured FDA alignment on the remaining early-stage trials needed to support an application to the agency seeking approval.
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 9 at 8:54 PM
TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns $TRVI $IWM $VXF https://stocktwits.com/news/equity/markets/trvi-stock-slips-after-company-plans-parallel-trials-in-lung-disease/cZdVDFCRIeE
0 · Reply
notreload_ai
notreload_ai Mar. 9 at 7:34 PM
$TRVI shares plunged despite positive FDA alignment for Haduvio in IPF chronic cough. Plans for two Phase 3 trials (instead of one) triggered sell-off; Stifel holds Buy rating on the de-risked program. https://notreload.xyz/fda-clears-path-for-haduvio-but-trevi-safe-two-trial-plan-sends-trvi-down/
1 · Reply
medguy
medguy Mar. 9 at 6:20 PM
Looking for bounce $OLMA $ORIC $TRVI $BRAI
0 · Reply
thefourpercent
thefourpercent Mar. 9 at 4:30 PM
$TRVI likely news will reflect after hours or pre market tomorrow. I’m In for a couple percent come back tomorrow
0 · Reply
abcdzepeda
abcdzepeda Mar. 9 at 4:01 PM
$TRVI interesting, we are down today after learning that the FDA meeting went well! 
0 · Reply
jlcrane
jlcrane Mar. 9 at 3:08 PM
$TRVI Can't wait for the good news.
0 · Reply
jlcrane
jlcrane Mar. 9 at 2:06 PM
$TRVI Knuckleheads!
0 · Reply
Chris2bucks4life
Chris2bucks4life Mar. 9 at 12:13 PM
$TRVI got the meeting should be all she wrote now ...
1 · Reply
StockNews_Live
StockNews_Live Mar. 9 at 11:31 AM
$TRVI Trevi Therapeutics, Inc. announced the results of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), gaining overall alignment on the plan for the remaining development progr…
0 · Reply
Chris2bucks4life
Chris2bucks4life Mar. 6 at 3:31 PM
$TRVI just won with dawn this is next buyout target for me we shall
1 · Reply
abcdzepeda
abcdzepeda Mar. 5 at 12:53 AM
$TRVI as soon as we get a little bit of Price movement, some start with the buyout hype. 
1 · Reply
Drew613
Drew613 Mar. 4 at 7:36 PM
$TRVI BO is right around the corner IMO. Very
1 · Reply
jlcrane
jlcrane Mar. 2 at 4:18 PM
$TRVI Time for the big short screwing!
1 · Reply
hmandude
hmandude Mar. 2 at 4:09 PM
$TRVI Been a little perky lately after bouncing off $10. Those 5k $12 March options that someone bought are up a lot.
0 · Reply